Hatch/Waxman Reform Should Await Pending Supreme Court Decision – Hatch
This article was originally published in The Tan Sheet
Executive Summary
Congress should wait for an upcoming Supreme Court ruling on the Doctrine of Equivalents before beginning serious work on re-drafting the Hatch/Waxman Act, Sen. Orrin Hatch (R-Utah) said
You may also be interested in...
Waxman’s Generic Reform: No 30-Month Stay, Early Declaratory Judgements
Rep. Henry Waxman (D-Calif.) is developing generic drug reform legislation that would eliminate the 30-month stay of approvals on ANDAs subject to patent litigation
Festo Ruling May Have Broad Implications In Hatch/Waxman Reform Debate
The Supreme Court's decision in the Festo case paves the way for continued debate on Hatch/Waxman patent reform, but could be a blow to generic drug firms
Three-Year Exclusivity Questioned By Sen. Edwards, GPHA’s Jaeger
Sen. John Edwards (D-N.C.) may be interested in re-examining the three-year market exclusivity provision under Hatch/Waxman as discussion on generic drug reform moves forward on Capitol Hill